Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BioNTech, Gilead, Memphasys - modern science and COVID and IVF

Mario Hose Mario Hose, news.financial
0 Comments| March 19, 2020

{{labelSign}}  Favorites
{{errorMessage}}

People around the world are worried about the extent of the consequences associated with the spread of the corona virus COVID-19, and politicians and the economy are called upon to deal with the situation appropriately so that the loss of life and financial damage to the citizens can be kept to a minimum. Medical experts are now working intensively to ensure that active substances for prevention and therapy are tested and made ready for the market.


Development of a vaccine

The German biotech company BioNTech (NASDAQ: BNTX) is working with renowned partners in China, Europe and the USA to develop a vaccine for the immunization and prevention of COVID-19 infections. A clinical trial is scheduled to start as early as April 2020. The company is pursuing the goal of making a vaccine available worldwide as quickly as possible. For this reason, BioNTech says it is "in close contact with various regulatory and scientific authorities around the world and is in ongoing discussions with other research institutions."


Investigational compound for corona viruses

US company Gilead Science (NASDAQ: GILD) is also working with global health authorities to counteract the outbreak of the new type of COVID-19 by using the investigational compound Remdesivir. Remdesivir has shown activity against MERS and SARS in animal studies, which are also corona viruses and show structural similarities to COVID-19. Since it is an experimental drug that has only been used in a small number of patients with COVID-19, Gilead is still in the early stages of development with Remdesivir.


Multi-billion growth market IVF

The Australian company Memphasys (ASX: MEM) focuses on the in vitro fertilisation (IVF) market for humans, which, according to Allied Market Research, currently has a global volume of USD 13.7 billion and is expected to grow to USD 26.4 billion by 2026. Memphasys focuses on the key element of a successful pregnancy for parents who want to have children: the quality of the used sperm. Sperm quality is declining worldwide, with one in three men over the age of 40 having problems with sperm fertility. About half of all infertility cases have poor sperm as an identifying factor.


Separation of sperm

Memphasys has developed an innovative device to separate and select sperm more quickly and effectively than current methods. The device called FELIX uses electric fields and membranes to sort the sperm according to quality and size. According to Alison Coutts, CEO of Memphasys, the better sperm has a greater net negative charge compared with faulty specimens.


Launching in Q3 2020

The company's next step is to support physicians in less regulated markets so that they can use the device commercially after completion of verification and validation, which is expected in mid 2020. At the same time, the company is working to obtain marketing approval from key regulatory authorities in Australia, the United States and Europe. While approval is a multi-year and costly process, Memphasys plans to sell early in countries with lighter regulation. These initial markets could include Japan, India, New Zealand and Canada.


CONFLICT OF INTEREST & RISK NOTE
We would like to point out that Apaton Finance GmbH, the owner of news.financial, as well as partners, authors or employees of Apaton Finance GmbH may hold shares in the aforementioned companies and that there may therefore be a conflict of interest. Further details can be found in our ´Conflict of Interest & Risk Disclosure´.


{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company